Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Core Viewpoint - The Gross Law Firm is notifying shareholders of Cassava Sciences, Inc. regarding a class action lawsuit related to the company's drug candidate simufilam, which failed to meet key study endpoints, leading to a significant drop in stock price [1][2]. Group 1: Allegations and Impact - The allegations state that Cassava Sciences provided misleading information about simufilam's effectiveness in treating Alzheimer's Disease, expressing confidence that was not supported by clinical results [1]. - On November 25, 2024, Cassava announced that simufilam did not meet any of the primary, secondary, or exploratory endpoints in its Phase 3 "ReThink-ALZ" study, resulting in a dramatic stock price decline of approximately 83.76%, from $26.48 to $4.30 per share in one day [1]. Group 2: Class Action Details - Shareholders who purchased shares of SAVA between February 7, 2024, and November 24, 2024, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for February 10, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case, with no cost or obligation to participate [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices and good corporate citizenship [3].